ERBB2 and metastatic neoplasm: Clinical data show that in approximately 30% of cases, the HER-2 status of distant metastatic tumor cells and CTCs are significantly different from that of cells in the primary site, suggesting that drugs targeting the primary tumor may not be appropriate for metastatic tumors.